Flare

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Nitrosamine, Anaphylaxis, Symantec Endpoint Protection, Absorption, Human, ARS, MAA, Patent, Caregiver, PD, New Drug Application, SAN, Patient, Adrenaline, Journal, CRL, NDA, American Academy, EMA, Quality of life, Trial of the century, Flare, American College, Investment, Clinical trial, Erythema, Lower respiratory tract infection, Asthma, Body surface area, Itch, Allergy, FDA, AAAAI, Total, Food, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the fourth quarter and full year 2023.

Key Points: 
  • In February 2024, ARS Pharma announced the successful completion of the repeat dosing study of neffy in seasonal allergic rhinitis under nasal allergen challenge conditions.
  • R&D Expenses: Research and development expenses were $3.4 million and $20.3 million for the quarter and year ended December 31, 2023, respectively.
  • G&A Expenses: General and administrative expenses were $6.8 million and $47.3 million for the quarter and year ended December 31, 2023, respectively.
  • Net Loss: Net loss was $7.2 million and $54.4 million for the quarter and year ended December 31, 2023, respectively.

SPEVIGO® approved for expanded indications in China and the US

Retrieved on: 
Tuesday, March 19, 2024
Arthralgia, Urinary tract infection, Uncertainty, Human, NMPA, Psoriasis, Disease, Multiple organ dysfunction syndrome, Incidence, Risk, GPP, Boehringer Ingelheim, Patient, Ageing, Executive officer, Immunoglobulin G, Anxiety, Doctor of Philosophy, MD, Quality of life, Flare, Injection site reaction, Clinical trial, Skin, Fever, Immune system, Pain, Itch, Food, FDA, Yale University, Fear

In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.

Key Points: 
  • In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.
  • “Until now, people living with GPP have not had any approved options to treat their disease,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, Yale University and Central Connecticut Dermatology.
  • “Experiencing GPP can be mentally and physically devastating, leaving those affected with uncertainty and fear of the next episode.
  • Therefore, expanding the treatment of GPP is a critical step towards addressing patients’ needs.”

Baker Hughes’ Emissions Abatement Technology Enables bp to Achieve Flare Emissions Monitoring Breakthrough

Retrieved on: 
Thursday, March 14, 2024
Carbon, Temperature, Pressure, Partnership, Part, Baker Hughes, Flare, Methane, BP, Natural gas

HOUSTON and LONDON, March 14, 2024 (GLOBE NEWSWIRE) --  Baker Hughes (NASDAQ: BKR), an energy technology company, has announced a breakthrough in flare emissions monitoring following a collaboration with bp .

Key Points: 
  • HOUSTON and LONDON, March 14, 2024 (GLOBE NEWSWIRE) --  Baker Hughes (NASDAQ: BKR), an energy technology company, has announced a breakthrough in flare emissions monitoring following a collaboration with bp .
  • Using Baker Hughes’ emissions abatement technology, flare.IQ , bp is quantifying methane emissions from its flares, a new application for the upstream oil and gas sector.
  • With no universally accepted solution to quantifying methane emissions from flares, bp and Baker Hughes conducted one of the largest ever full-scale studies of flare combustion, including testing a range of flares under challenging conditions and verifying the accuracy of flare.IQ technology.
  • Alongside flare.IQ, Baker Hughes has a broad, proven portfolio of emissions abatement technologies capable of improving productivity, efficiency and delivering increased value at scale across customer operations.

Thermal Countermeasure Market - Global and Regional Analysis and Forecasts, 2023-2033: Utilization of 3D Printing in Manufacturing and Improved Capabilities through Integration with IoT - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Defense, IOT (Internet of Things), Technology, Other Technology, Audio, Video, Military, Other Defense, Flare, World War II, War, Growth, Country, Environment, Weapon, Anglo-French Wars, UAV, Light, Electronics, History, Military personnel, DIRCM, Traction, Safety, Aircraft, Region, Ceramic

The "Thermal Countermeasure Market - A Global and Regional Analysis: Focus on Platform, Product Type, Integration Type, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thermal Countermeasure Market - A Global and Regional Analysis: Focus on Platform, Product Type, Integration Type, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Thermal countermeasures represent a key breakthrough in modern fighting and defensive methods, notably in military and security situations.
  • Moreover, favorable government policies are also expected to support the growth of the thermal countermeasures market in North America and Europe during the forecast period.
  • In North America, the U.S. is anticipated to show the highest growth in the thermal countermeasures market among other countries in North America.

NEW RESEARCH FINDS ADULTS, CHILDREN AND TEENS WITH ECZEMA EXPERIENCE SIGNIFICANT MENTAL HEALTH SYMPTOMS

Retrieved on: 
Wednesday, March 27, 2024
Research, Depression, Atopic dermatitis, Mental, Caregiver, Patient, CQD, Mental health, Child, Anxiety, Dermatitis, Flare, Pleasure, NEA, Emotion, Nursing

NOVATO, Calif., March 27, 2024 /PRNewswire/ -- The National Eczema Association (NEA) today announced the first publication from its real-world research on eczema and its impacts on mental health. The results were published in the journal Dermatitis in March 2024.

Key Points: 
  • In a new study, the NEA research team aimed to evaluate patient-reported mental health symptoms, their correlation with eczema severity, and patient-perceived associations of eczema and its impacts on mental health.
  • The survey included questions about eczema symptoms, mental health symptoms, perceptions of the connection between eczema and mental health, and experiences accessing mental health services.
  • The study findings illustrated that adults, children and teens with eczema experience a significant mental health burden that increases with eczema severity:
    70% of respondents reported that either their own or their child's mental health was impacted by eczema during the past year.
  • Those with more severe eczema symptoms were more likely to have 10+ days of poor mental health than those with less severe eczema symptoms.

Global Thermal Countermeasure Industry Research 2023-2033: Ongoing and Upcoming Programs, Technological Trends, Competitive Benchmarking

Retrieved on: 
Wednesday, March 27, 2024
Flare, World War II, War, Growth, Country, Environment, Weapon, Anglo-French Wars, UAV, Light, Electronics, History, Military personnel, DIRCM, Traction, Safety, Aircraft, Region, Ceramic

Moreover, favorable government policies are also expected to support the growth of the thermal countermeasures market in North America and Europe during the forecast period.

Key Points: 
  • Moreover, favorable government policies are also expected to support the growth of the thermal countermeasures market in North America and Europe during the forecast period.
  • In North America, the U.S. is anticipated to show the highest growth in the thermal countermeasures market among other countries in North America.
  • Thermal countermeasures include a variety of devices meant to deceive or reduce the efficacy of thermal sensors and infrared detection systems.
  • An increase in military modernization programs by the defense industry is driving the growth of the thermal countermeasures industry.

Flotek Reports Fourth Quarter and Full-Year 2023 Results Highlighted by Growth in All Profitability Metrics Including a $31 Million Improvement in Annual Gross Profit

Retrieved on: 
Tuesday, March 12, 2024
Solidified, The Ritz-Carlton Hotel Company, Administration, Conference, Growth, Data analysis, EPS, Telephone, Flare, News, Chemistry, EPA, ABL, GAAP, JP3, Video game

Gross Profit (Loss): The Company generated gross profit of $9.4 million during the fourth quarter 2023 as compared to a gross loss of $2.1 million for the fourth quarter 2022.

Key Points: 
  • Gross Profit (Loss): The Company generated gross profit of $9.4 million during the fourth quarter 2023 as compared to a gross loss of $2.1 million for the fourth quarter 2022.
  • Adjusted Gross Profit (Non-GAAP)(1): Flotek generated adjusted gross profit(1) of $10.7 million during the fourth quarter 2023 compared to adjusted gross loss(1) of $0.5 million for the fourth quarter 2022.
  • Selling, General and Administrative ("SG&A") Expense: SG&A expense totaled $6.6 million for the fourth quarter 2023 compared to $6.2 million for the fourth quarter 2022.
  • Adjusted EBITDA (Non-GAAP)(1): Adjusted EBITDA(1) was $4.0 million in the fourth quarter 2023 as compared to negative $5.1 million in the fourth quarter 2022.

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

Retrieved on: 
Monday, February 26, 2024
SAN, Incidence, The Study, AAAAI, Caregiver, Angioedema, Histamine, Principal, ARS, FDA, Quality of life, Anaphylaxis, Body surface area, Data, Convention center, Skin, Safety, Joint task force, Allergy, Patient, Flare, Data analysis, CSU, Erythema, Pediatrics, Asthma, Adrenaline, Itch, American Academy, Pharmaceutical industry

Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.

Key Points: 
  • Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.
  • “Urticaria is not only a standalone type I allergy disease, but also represents the most frequent symptom observed during type I allergic reactions including anaphylaxis.
  • neffy may provide episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients.
  • This would follow the anticipated FDA approval of neffy for allergic reactions (Type I) including anaphylaxis in the second half of 2024.

Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasis

Retrieved on: 
Friday, March 8, 2024
Health, Health Technology, Other Science, General Health, Clinical Trials, Research, Science, Therapy, Incidence, Natural history, Woman, GPP, Registry, Quality of life, RWE, Thermo Fisher Scientific, Prevalence, PPD, Rash, Patient, Flare, Autoimmunity, Yale University, Disease

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP).

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP).
  • This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.
  • Thermo Fisher acquired CorEvitas, a leading provider of gold-standard real-world evidence solutions, in August 2023.
  • The registry was launched with clinical guidance from two leading GPP clinical experts who serve as scientific advisors: Dr. Mark Lebwohl, dean for clinical therapeutics, Icahn School of Medicine at Mount Sinai; and Dr. Bruce Strober, clinical professor, Department of Dermatology at Yale University.

Healthcare Innovation Company Announces Investor-Led Panels on the Latest Trends for Healthcare, Navigating Generative AI at Its Annual thINc360 Event, May 29-31, in D.C.

Retrieved on: 
Thursday, March 7, 2024
Flare, EVP, Independence Blue Cross, Gen, General partnership, CareFirst BlueCross BlueShield, Venture capital, Content, Corporate development, Ecosystem, Partner (business rank), Congress, IBX, CIO

NEEDHAM, Mass., March 7, 2024 /PRNewswire-PRWeb/ --The Healthcare Innovation Company announced the addition of more investor perspectives at its upcoming thINc360 event, taking place May 29-31, in Washington, D.C, including:

Key Points: 
  • While so much of the recent buzz is centered on generative AI, and rightly so, there is so much more to explore when it comes to other investment opportunities and evaluating practical next steps with new technologies and burgeoning solutions.
  • We are excited to bring the investor and startup communities together in a large forum and continue our mission to further innovation in healthcare," said Haritha Krishnarathnam, EVP of Strategy and Content, at The Healthcare Innovation Company.
  • Additional investor insights at thINc360 will be delivered by:
    Endeavor Venture Funds & Venture Studio, Managing Partner and CIO, Martin Alexander Gershon
    Early registration deadlines are in effect, with the next one expiring on Friday, March 15.
  • Prospective attendees and sponsors are encouraged to visit https://www.thinc360.com/2024event for more information.